Loading...

Leslie Ballas, MD

Title(s)Associate Professor of Clinical Radiation Oncology
Phone+1 323 865 3050
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Leslie Ballas is an Associate Professor of Clinical Radiation Oncology at USC Norris Cancer Hospital. She received her undergraduate degree from Cornell University, and her Medical Doctorate degree from the University of Michigan. She did her internship at Cornell in Surgery and her residency in Radiation Oncology at Cornell.

    After residency, Dr. Ballas spent time on the faculty at MD Anderson Cancer Center treating hematologic malignancies (leukemia, lymphoma and multiple myeloma). She has considerable experience treating this patient population. Because many lymphomas are highly curable, management of long term side effects from treatment is essential. She uses a variety of treatment techniques and modalities to minimize radiation dose to normal structures, thereby minimizing late effects from treatment. She also has a great deal of experience working with cutaneous lymphomas and the management of this category of lymphomas.

    Dr. Leslie Ballas also specializes in cancers of the genitourinary tract, including malignancies of the prostate, urinary bladder, testicle, and kidney. Her research has focused on improving quality of life for men with prostate cancer. She is involved in the development of cancer treatment clinical trials for patients with genitourinary cancers. And has brought multiple genitourinary cooperative group studies to USC. Dr. Ballas’ interests include advanced technology integration into cancer therapeutics, including image-guide radiation therapy (IGRT), stereotactic body radiotherapy (SBRT), and intensity modulated radiotherapy (IMRT).

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Pham A, Ballas LK. Trimodality therapy for bladder cancer: modern management and future directions. Curr Opin Urol. 2019 May; 29(3):210-215. PMID: 30855374.
      View in: PubMed
    2. England JR, Paluch J, Ballas LK, Jadvar H. 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA = 1 ng/mL After Definitive Primary Treatment. Clin Nucl Med. 2019 Mar; 44(3):e128-e132. PMID: 30589673.
      View in: PubMed
    3. Ballas LK, Luo C, Chung E, Kishan AU, Shuryak I, Quinn DI, Dorff T, Jhimlee S, Chiu R, Abreu A, Jennelle R, Aron M, Groshen S. Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. Int J Radiat Oncol Biol Phys. 2019 May 01; 104(1):50-60. PMID: 30605751.
      View in: PubMed
    4. Bateni ZH, Pearce SM, Zainfeld D, Ballas L, Djaladat H, Schuckman AK, Daneshmand S. National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013. Eur Urol Oncol. 2018 Dec 19. PMID: 31317867.
      View in: PubMed
    5. Kraus RD, Barsky A, Ji L, Garcia Santos PM, Cheng N, Groshen S, Vapiwala N, Ballas LK. The Perineural Invasion Paradox: Is Perineural Invasion an Independent Prognostic Indicator of Biochemical Recurrence Risk in Patients With pT2N0R0 Prostate Cancer? A Multi-Institutional Study. Adv Radiat Oncol. 2019 Jan-Mar; 4(1):96-102. PMID: 30706016.
      View in: PubMed
    6. Sargos P, Baumann BC, Eapen L, Christodouleas J, Bahl A, Murthy V, Efstathiou J, Fonteyne V, Ballas L, Zaghloul M, Roubaud G, Orré M, Larré S. Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. Cancer Treat Rev. 2018 Nov; 70:88-97. PMID: 30125800.
      View in: PubMed
    7. Kraus RD, Hamilton AS, Carlos M, Ballas LK. Using hospital medical record data to assess the accuracy of the SEER Los Angeles Cancer Surveillance Program for initial treatment of prostate cancer: a small pilot study. Cancer Causes Control. 2018 Sep; 29(9):815-821. PMID: 30022335.
      View in: PubMed
    8. Naser-Tavakolian A, Tran C, Timoteo M, Chiu R, Ballas L. Novel Treatment Setup for Urethral Cancer: Use of the Prone Technique for Radiotherapy of the Penis. Case Rep Oncol. 2018 May-Aug; 11(2):268-275. PMID: 29867434.
      View in: PubMed
    9. Ballas LK, Kraus R, Ji L, Groshen S, Stern MC, Gill I, Quinn DI, Chung E, Abreu A, Hamilton AS. Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital? Clin Genitourin Cancer. 2018 08; 16(4):e719-e727. PMID: 29483045.
      View in: PubMed
    10. Jadvar H, Ballas LK. PSMA PET: Transformational Change in Prostate Cancer Management? J Nucl Med. 2018 02; 59(2):228-229. PMID: 29242400.
      View in: PubMed
    11. Dorff TB, Ballas LK, Schuckman AK. Current Management Strategy for Penile Cancer and Future Directions. Curr Oncol Rep. 2017 Aug; 19(8):54. PMID: 28664471.
      View in: PubMed
    12. Yoon J, Ballas L, Desai B, Jadvar H. Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting 18F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical Prostatectomy. World J Nucl Med. 2017 Jul-Sep; 16(3):229-236. PMID: 28670183.
      View in: PubMed
    13. Yu SS, Ballas LK, Skinner EC, Dorff TB, Sadeghi S, Quinn DI. Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clin Adv Hematol Oncol. 2017 Jul; 15(7):543-551. PMID: 28749918.
      View in: PubMed
    14. Yu SS, Dorff TB, Ballas LK, Sadeghi S, Skinner EC, Quinn DI. Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. Clin Adv Hematol Oncol. 2017 Jun; 15(6):466-477. PMID: 28749907.
      View in: PubMed
    15. Ballas L, Sargos P, Orré M, Bian SX, Daneshmand S, Eapen LJ. Tolerance of Orthotopic Ileal Neobladders to Radiotherapy: A Multi-institutional Retrospective Study. Clin Genitourin Cancer. 2017 12; 15(6):711-716. PMID: 28558986.
      View in: PubMed
    16. Baumann BC, Sargos P, Eapen LJ, Efstathiou JA, Choudhury A, Bahl A, Murthy V, Ballas LK, Fonteyne V, Richaud PM, Zaghloul MS, Christodouleas JP. The Rationale for Post-Operative Radiation in Localized Bladder Cancer. Bladder Cancer. 2017 Jan 27; 3(1):19-30. PMID: 28149931.
      View in: PubMed
    17. Winkfield KM, Advani RH, Ballas LK, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Younes A, Constine LS. ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. Oncology (Williston Park). 2016 12 15; 30(12):1099-103, 1106-8. PMID: 27987203.
      View in: PubMed
    18. Dhakal S, Advani R, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. Am J Clin Oncol. 2016 12; 39(6):535-544. PMID: 27643717.
      View in: PubMed
    19. Ballas LK, de Castro Abreu AL, Quinn DI. What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer. J Nucl Med. 2016 Oct; 57(Suppl 3):6S-12S. PMID: 27694176.
      View in: PubMed
    20. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol. 2016 Aug 01; 2(8):1065-9. PMID: 27227654.
      View in: PubMed
    21. Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L, Lewinger JP, Stern MC, Hamilton AS, Aron M, Gill IS. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. J Urol. 2015 Aug; 194(2):378-85. PMID: 25711194; PMCID: PMC4834920.
    22. Ballas L. Modern radiotherapeutic strategies in the management of lymphoma. Future Oncol. 2015; 11(6):1011-20. PMID: 25760980.
      View in: PubMed
    23. Ballas LK, Hu BR, Quinn DI. Chromoplexy and hypoxic microenvironment drives prostate cancer. Lancet Oncol. 2014 Dec; 15(13):1419-21. PMID: 25456359.
      View in: PubMed
    24. Jhaveri PM, Sun Z, Ballas L, Followill DS, Hoffman KE, Jiang J, Smith BD. Emergence of integrated urology-radiation oncology practices in the State of Texas. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):15-9. PMID: 22789491.
      View in: PubMed
    25. Dabaja B, Wang Z, Stovall M, Baker JS, Smith SA, Khan M, Ballas L, Salehpour MR. Involved field radiation for Hodgkin's lymphoma: the actual dose to breasts in close proximity. Med Dosim. 2012; 37(4):374-82. PMID: 22513213.
      View in: PubMed
    26. Shihadeh F, Reed V, Faderl S, Medeiros LJ, Mazloom A, Hadziahmetovic M, Kantarjian H, Allen P, Ballas L, Pierce S, Dabaja B. Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. Cancer. 2012 Jan 01; 118(1):112-7. PMID: 21692072.
      View in: PubMed
    27. Lebwohl B, Ballas L, Cao Y, Chan G, Grossman R, Sherr DL, Woodhouse S, Neugut AI. Treatment interruption and discontinuation in radiotherapy for rectal cancer. Cancer Invest. 2010 Mar; 28(3):289-94. PMID: 20073579.
      View in: PubMed
    28. Hei TK, Ballas LK, Brenner DJ, Geard CR. Advances in radiobiological studies using a microbeam. J Radiat Res. 2009 Mar; 50 Suppl A:A7-A12. PMID: 19346688.
      View in: PubMed
    29. Ballas LK, Elkin EB, Schrag D, Minsky BD, Bach PB. Radiation therapy facilities in the United States. Int J Radiat Oncol Biol Phys. 2006 Nov 15; 66(4):1204-11. PMID: 17145535.
      View in: PubMed
    30. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 1996 May 03; 272(5262):728-31. PMID: 8614835.
      View in: PubMed